Forest Lexapro for panic disorder
This article was originally published in Pharmaceutical Approvals Monthly
Forest's April 30 submission of Lexapro (escitalopram) for the treatment of panic disorder is the fourth supplement for the antidepressant, which has had one of the strongest launches in history following its Aug. 14, 2002 approval for treatment of depression. The drug gained a maintenance claim Aug. 29, 2002, and an oral solution formulation was cleared in November 2002. An sNDA for generalized anxiety disorder was submitted in November 2002 and a social anxiety disorder filing is slated for "late in the fiscal year." Forest projects that the Celexa follow-on will lead the selective serotonin reuptake inhibitor market by 200
You may also be interested in...
CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.
Only 12 US jurisdictions currently have sound COVID-19 virus assays from the Centers for Disease Control and Prevention to test suspected virus cases, CDC director Robert Redfield told a House panel looking at virus preparedness on Wednesday – but a better batch is coming, he said. Other questions raised at the congressional hearing was how long an infected person stays infected, whether COVID-19 can be picked up from inanimate surfaces, and related queries.
Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps.